Your browser is no longer supported. Please, upgrade your browser.
Index- P/E- EPS (ttm)-4.81 Insider Own- Shs Outstand21.62M Perf Week-0.57%
Market Cap150.67M Forward P/E- EPS next Y-3.39 Insider Trans- Shs Float14.18M Perf Month1.01%
Income- PEG- EPS next Q- Inst Own6.29% Short Float0.01% Perf Quarter-39.78%
Sales3.72M P/S40.53 EPS this Y-12.40% Inst Trans- Short Ratio0.26 Perf Half Y6.90%
Book/sh1.32 P/B5.27 EPS next Y22.10% ROA- Target Price- Perf Year54.89%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range5.00 - 13.95 Perf YTD-24.49%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.04% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low39.40% ATR0.32
Employees206 Current Ratio- Sales Q/Q-40.90% Oper. Margin- RSI (14)44.80 Volatility2.38% 3.80%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.04 Prev Close7.03
ShortableYes LT Debt/Eq- EarningsMay 04 AMC Payout- Avg Volume6.86K Price6.97
Recom1.70 SMA20-1.17% SMA50-5.87% SMA200-12.52% Volume14,008 Change-0.85%
May-07-21 12:00PM  
May-04-21 04:30PM  
Apr-29-21 02:30AM  
Apr-28-21 07:30PM  
Apr-20-21 01:30AM  
Apr-19-21 01:30AM  
Apr-07-21 04:30PM  
Mar-09-21 04:30PM  
Mar-08-21 04:30PM  
Mar-05-21 12:00PM  
Mar-04-21 04:30PM  
Feb-24-21 04:30PM  
Feb-10-21 04:30PM  
Feb-08-21 01:30AM  
Feb-04-21 01:00PM  
Jan-25-21 04:30PM  
Jan-14-21 04:30PM  
Jan-13-21 08:36AM  
Jan-06-21 04:30PM  
Jan-04-21 02:00AM  
Dec-14-20 04:30PM  
Dec-10-20 04:30PM  
Dec-07-20 02:00AM  
Dec-03-20 04:30PM  
Nov-12-20 04:30PM  
Nov-05-20 04:30PM  
Nov-04-20 12:00PM  
Nov-02-20 03:19AM  
Oct-29-20 05:30PM  
Oct-26-20 05:30PM  
Oct-12-20 05:51AM  
Sep-21-20 04:45PM  
Sep-16-20 04:30PM  
Sep-14-20 04:30PM  
Aug-06-20 12:00PM  
Jul-10-20 12:00PM  
Jun-26-20 04:30PM  
Jun-25-20 08:26AM  
Jun-09-20 12:00PM  
Jun-02-20 04:30PM  
Jun-01-20 01:30AM  
May-26-20 04:00PM  
May-07-20 12:00PM  
May-06-20 04:30PM  
May-05-20 04:30PM  
Apr-30-20 04:30PM  
Apr-28-20 06:13PM  
Apr-20-20 04:30PM  
Apr-06-20 12:00PM  
Mar-19-20 06:00PM  
Mar-16-20 06:05PM  
Mar-12-20 05:30PM  
Mar-06-20 12:00PM  
Feb-26-20 05:00PM  
Feb-20-20 04:30PM  
Feb-04-20 12:00PM  
Feb-03-20 06:43AM  
Jan-24-20 01:30AM  
Jan-14-20 08:29AM  
Jan-10-20 11:45AM  
Dec-02-19 12:00PM  
Nov-25-19 01:30AM  
Nov-14-19 05:00PM  
Nov-07-19 05:00PM  
Nov-05-19 05:00PM  
Nov-04-19 01:30AM  
Oct-04-19 12:00PM  
Sep-18-19 03:54AM  
Sep-17-19 05:00PM  
Sep-11-19 05:00PM  
Sep-03-19 11:51AM  
Aug-02-19 11:45AM  
Jul-23-19 05:07PM  
Jul-16-19 05:02PM  
Jul-02-19 12:01PM  
Jun-26-19 05:01PM  
Jun-24-19 05:32PM  
May-31-19 12:05PM  
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.